Table 2.
Model 1 | Model 2 | |||
---|---|---|---|---|
Beta | p value | Beta | p value | |
Cholesterol (total) | 0.003 | 0.86 | 0.010 | 0.6 |
Triglycerides | 0.071 | <0.01 | 0.070 | <0.01 |
HDL-c | -0.080 | <0.01 | -0.070 | <0.01 |
LDL-c | 0.011 | 0.52 | 0.020 | 0.4 |
Large VLDL-P | 0.004 | 0.83 | 0.002 | 0.9 |
Medium VLDL-P | -0.001 | 0.94 | -0.002 | 0.9 |
Small VLDL-P | -0.011 | 0.53 | -0.011 | 0.5 |
Large IDL-P | 0.010 | 0.54 | 0.013 | 0.5 |
Small IDL-P | -0.042 | 0.02 | -0.037 | 0.03 |
Large LDL-P | 0.009 | 0.60 | 0.009 | 0.6 |
Medium LDL-P | 0.047 | 0.01 | 0.045 | 0.01 |
Small LDL-P | 0.039 | 0.03 | 0.038 | 0.03 |
Very small LDL-P | 0.039 | 0.02 | 0.040 | 0.02 |
Total LDL-P | 0.038 | 0.03 | 0.037 | 0.04 |
Large HDL-P | -0.068 | <0.01 | -0.062 | <0.01 |
Small HDL-P | 0.002 | 0.92 | -0.002 | 0.92 |
Total HDL-P | -0.026 | 0.13 | -0.026 | 0.13 |
High-risk LDL-P∗ | 0.049 | 0.01 | 0.047 | 0.01 |
∗High-risk LDL-P contains very small, small, and medium LDL particles. Model 1 controlled for heart rate (measured from the carotid artery), mean arterial pressure at the time of the c-fPWV measurements, age at time of c-fPWV measurement, gender, fasting glucose ≥ 7 mmol, waist-to-hip circumference at baseline, smoking status at baseline, and whether participants were taking blood pressure-lowering medications and/or lipid-lowering medications at follow-up. Model 2 included the variables in Model 1 plus natural log transformed C-reactive protein. Abbreviations: HDL-c: high-density lipoprotein cholesterol; HDL-P: high-density lipoprotein particles; IDL-P: intermediate-density lipoprotein particles; LDL-c: low-density lipoprotein cholesterol; LDL-P: low-density lipoprotein particles; VLDL-P: very low-density lipoprotein particles.